Prevalence of Advanced HIV Disease
Ever since the adoption of the WHO guidelines for clinical management of AHD in Uganda in 2020, this is the first published study to evaluate the prevalence and clinical management of new and non-suppressed HIV patients with AHD in Uganda. From the analysis of a sample of 994 treatment naïve HIV patients at a non-profit health facility in Western Uganda, the prevalence of ADH as defined by a CD4 cell count below 200 cells/µl or WHO clinical stage 3 or 4 disease was 20.4%. However, the prevalence differed in different groups, with males having a higher prevalence than the females (30.3% versus 13.9%) and children under 10 years having the highest prevalence at 65.2% while the least prevalence of AHD was among the adolescents 16.1%. These findings are consistent with those from several other studies which have demonstrated that males are more likely than males to present with AHD [8, 16–18]. A national HIV cohort study conducted in South Africa from 2004 to 2016 found that men were almost than twice as likely to enrol into care with AHD (23.1% vs 12.6%) [16]. The high AHD prevalence among men adds to the existing regional data revealing the failure of HIV programs to attract men [11].
This study also found that there was no difference in access to CD4 testing between the two groups is explained by similar quality of care between the treatment naïve and non-suppressed patients. This similar access to CD4 testing is attributed to Uganda Ministry of Health guidelines which highlight the importance of AHD screening in both the treatment naïve and non-suppressed patients because these groups are the ones who are at risk of subclinical OIs and require CD4 testing and comprehensive clinical examination to determine if they have stage 3 or 4 disease for further management [12].
Additionally, the high AHD prevalence among men is attributed to delayed diagnosis of HIV infection and linkage to care and treatment services. Several initiatives have been put in place throughout Africa to promote HIV testing and patient enrolment in ART, but little progress has been made in locating and enlisting men for HIV treatment. Attracting men for HIV testing has been the main barrier because very few men are found and consented to HIV testing services [19]. Even the increase of HIV testing and treatment under the test and treat strategy has mostly benefited more women than men, widening the gap between male and female life expectancy [19].
The high prevalence of AHD among both treatment naïve and non-suppressed patients is attributed to the fact that they are not on treatment, or they are non-adherent to the treatment or on ineffective treatment [18]. With the current Ministry of Health test and treat policy [20], where all HIV positive patients are started on HAART the prevalence of AHD is expected to reduce. Additionally, interventions for viral re-suppression for patients already on ART are within the policy in Uganda, therefore it is critical that these are implemented to fidelity to achieve HIV epidemic control. For-example, the WHO recommends that patients who are virologically unsuppressed receive at least three Intensive Adherence Counselling (IAC) to achieve viral suppression again [21]. This intervention is known to achieve viral suppression in over 70.5% of HIV patients with viraemia [21].
Management of Advanced HIV Disease
In this study conducted in the private not for profit facility in South Western Uganda, the prevalence of AHD was relatively high and this warrants provision of the WHO AHD care package [3]. The WHO package of care for AHD includes rapid ART initiation, screening, diagnosis and management TB and cryptococcal disease, cotrimoxazole prophylaxis, Isoniazid prophylaxis as well as adherence support [3]. In line with these recommendations, Meya et al, published guidance on the indicators and targets for monitoring implementation of the AHD package [12]. For-example, every patient with a positive HIV test should receive a CD4 count [12]. In addition, serum CrAg screening and LAM or Xpert MTB assay should be done for all those with s CD4 count less than 200 cells/ml and all those positive tests should started on the appropriate treatment in line with the national guidelines [12].
The findings from this study demonstrate an average access to AHD screening using CD4 testing among both the ART naïve (74.5%) and virally unsuppressed patients (77.6%). These finding are consistent with those from inpatient settings in Malawi (65.1%) and Botswana (85.9%) [9, 11]. Increasing access to CD4 testing is a great opportunity in the management of AHD as it helps in identifying asymptomatic patients with AHD and therefore prompt clinicians to initiate timely interventions [12]. To improve the diagnosis and management of AHD, HIV control programs ought to expand access to CD4 testing using interventions such as the Point of Care (POC) such as the VISITECT lateral flow assay, a semi-quantitative assay that reports CD4 results as a binary measure of less than 200 or greater than 200 cells/ml [22, 23].
This study also found that 100% of all newly diagnosed patients started ART within seven days from the date of diagnosis. In addition, 93% of the patients initiating ART received a dolutegravir-based regime which is the preferred first-line medication according to the WHO recommendations. ART is the most important intervention for preventing AHD related deaths [22]. It is critical to quickly start or restart ART with regimens that rapidly reduce viral load with low side effects, such as integrating inhibitor-based regimens regardless of the CD4 count or WHO clinical stage. Our findings differ from those from a similar study in Senegal where only about 33% of newly diagnosed patients-initiated ART within seven days of diagnosis [8]. This is largely attributed to differences in the study setting; whereas significant gains have been made on the UNAIDS 95 95 95 targets in Uganda and other East African countries, there has been slow progress in West and Central African countries where it is estimated that only about 48% of PLHIV know their HIV status [8].
Regarding prophylaxis of opportunistic infections, all the new enrolled HIV patients received Sulphamethoxazole-Trimethoprim (cotrimoxazole) prophylaxis while 6 in 10 patients who did not have TB symptoms received a six-month course of Isoniazid for TB prophylaxis in line with the national guidelines. These findings differ from those from a similar cross-sectional study in Senegal where only 65% new PLHIV received cotrimoxazole prophylaxis and none (0%) received Isoniazid Preventive Treatment [8]. The barriers to optimal Isoniazid uptake include Isoniazid stock-out, concerns about the development of Isoniazid drug resistance, low patient acceptance, provider concerns about drug interactions, limited of awareness of the eligibility criteria and a lack of commitment on the part of health managers to scale up the intervention [8, 24].
Uganda TB guidelines recommend the use of urine TBLAM in patients with AHD who are very ill and have CD4 counts less than 200 cells/ml [25]. Our findings also demonstrate that whereas access to TB symptom screening is universally done (100%), there is sub-optimal access to urine TBLAM testing with only 44.4% (96/216) laboratory evaluation and 23 TB patients diagnosed and treatment initiated. These findings are consistent with those from a 2022 Tanzanian retrospective cohort study of 2624 patient records, which assessed the implementation of the WHO TB-related AHD care package and its impact on HIV patient outcomes [10]. In Tanzania, among the 716 HIV patients with AHD, only 5% had diagnostic assessment using Xpert MTB assay; urine TBLAM assay was generally not done (0%) [10]. These findings illustrate that despite being a user-friendly test, pain-free and safe, TBLAM testing is not optimally done.
Evidence from a Randomised Controlled Trial in Tanzania and Zambia suggests that targeted CrAg screening and pre-emptive treatment with fluconazole reduces the incidence and mortality from cryptococcal meningitis [26]. However, the findings from this study in Uganda demonstrate that 6 in 10 patients with AHD had CrAg screening done, of which 12 patients were found to have a positive serum CrAg result and they all received pre-emptive treatment with fluconazole. Despite the Ministry of Health recommendation to conduct a lumber puncture and CSF CrAg for all patients with a positive serum CrAg, none of the patients had a lumber punctured done. These findings are consistent with those from another study in Uganda which evaluated implementation of a cryptococcal antigen screening program in Central and Southwestern Uganda which found that CrAg screening was done for 71% of the AHD patients, 83.9% were initiated on pre-emptive treatment with fluconazole, and 69.6 had a lumber puncture done [27]. These findings demonstrate significant successes in CrAg screening as well as some gaps along the cryptococcal disease management cascade.
Integration of routine CrAg screening for patients with AHD and pre-emptive treatment with fluconazole into HIV programs is cost effective and is associated with reduced occurrence of cryptococcal meningitis and an overall reduction of HIV related deaths [27]. In a Uganda cost-effectiveness analysis model for evaluating the national cryptococcal screening program, it was found that, CrAg screening and treatment saved 7320 lives at a cost of $459 per life saved. On the other hand, without CrAg screening, the cost of one week treatment of a patient with cryptococcal meningitis using Amphotericin B and Flucytosine is $1861 [28]. This makes CrAg screening and pre-emptive treatment with fluconazole more cost-effective than treatment of established meningitis [12, 28].
Barriers and facilitators to AHD Screening and management
A qualitative study conducted at a secondary referral hospital in Malawi found the following to be barriers to optimal delivery of a complete AHD package including screening, prophylaxis, diagnosis and management [29]. These include complexity of the intervention, weak coordination of work, inadequate resources to scale-up point of care diagnostic services for AHD, and knowledge and information gaps among service providers [29]. Implementation of AHD was reported by providers to be cumbersome requiring the involvement of different departments, several laboratory investigations which prolong patient waiting time. Each newly diagnosed HIV patient had to go through several tests including CrAg and TBLAM if CD4 is less than 200 cell/ml; before they were linked to treatment [29].
The lack of resources of AHD screening and management was also reported as a barrier by Mithi et al. These resources included posters, testing algorithms or Standard Operating Procedures, laboratory equipment such as centrifuges, pipettes, and waste management facilities as well as lack of training on how to conduct point of care tests such as TBLAM and CrAg [29]. Furthermore, in Uganda, Lofgren et al, found challenges of inadequate supply of medicines including fluconazole which affected the quality of AHD care [30].
Still, in Malawi, the inadequate coordination of work was attributed to the long distance between the ART clinic and the laboratory which caused loss of patients between the two departments. Additionally, the absence of communication systems such as a telephone hindered communication between the different teams and departments thus compromising service delivery [29]. This information is helpful for health managers to identify where the bottlenecks are and guides in the development of a mitigation plan to address the barriers.
The possible facilitators for optimal implementation of AHD screening, diagnosis and management include availability of policy documents including guidelines and Standard Operating Procedures, adequate external support by the Ministry of Health and PEPFAR implementing partners in the form of human resources, data collection tools, program review meetings, as well integrated mentorships and supportive supervision [29].
Additionally, the presence of trained AHD implementation leads who also served as ART focal persons helps to facilitate successful implementation [29]. Similarly, in Uganda, selecting a focal point person for CrAg testing at each health facility was helpful. This staff was responsible for following up patients who tested positive for CrAg for timely assessment and treatment [30].
The other facilitators reported in health facilities in Uganda include having an appropriate quantity of CrAg testing kits, having positive interactions between trainers and clinic staff, and training of providers about cryptococcal disease [30]. This information on the facilitators is helpful for health managers and policy makers to identify areas which need to be enhanced for successful implementation of the intervention.
Study strength and limitations
This study had several strengths, first, this study used a representative sample of 994 of treatment naïve patients who were enrolled at the TASO clinic. The study utilized secondary data which was routinely collected and entered the national electronic medical records system and updated weekly. This made the process of data acquisition easier considering the short research timeline.
Secondly, the data were valid because they were generated by a team of qualified and trained health workers including medical officers, clinical officers, counsellors, laboratory staff and nurses. These health workers had training in advanced HIV disease management and had medical licenses by their respective professional bodies. Additionally, validity of the tests conducted was ensured through internal and external quality assurance mechanisms coordinated through the Uganda Virus Research Institute and the National TB and Reference Laboratory.
There is no published study in Uganda that has evaluated the current practices in the management of AHD considering the WHO and Ministry of Health recommendations. This study elucidates the level of implementation and adherence to current standards for AHD and highlights the gaps along the cascade that the government need to address to improve implementation of these guidelines to fidelity.
Limitations
This study had some limitations. This study being a descriptive cross-section study means that the study utilized data at one specific point in time from January 2020 to December 2022 after the integration and roll-out of AHD guidelines. This therefore means that findings of this study are likely to change with time as the AHD interventions are scaled-up and adopted at more health facilities. Also, this being a retrospective review of patient records, is subject to information bias because of incorrect documentation or missing data (lack of documentation). This challenge was mitigated by verifying the electronic data with paper-based registers and any missing entries were filled.
Additionally, some categories of clients, such as those re-engaging into care after interruption in treatment were not included in this analysis since there was no standardized system of capturing AHD screening and management data for this category of clients in health facilities. Lastly, this study was conducted in only one high volume nonprofit health facility, therefore, the findings of this study may not be generalizable nor be used to make inferences about the status of AHD screening and management practices in other settings in Uganda, because: first, patients attending nonprofit health facilities may have different characteristics than those attending public health facilities, second, the clinical practices may also differ in different settings; third, urban and rural implementation may also differ due to unique health system challenges in the rural settings.